Janice McCourt - 14 Oct 2023 Form 4 Insider Report for Comera Life Sciences Holdings, Inc.

Role
Chief Business Officer
Signature
/s/ Ryan M. Rourke Reed, Attorney-in-Fact
Issuer symbol
CMRA on OTC
Transactions as of
14 Oct 2023
Net transactions value
$0
Form type
4
Filing time
16 Oct 2023, 16:59:06 UTC
Previous filing
09 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMRA Stock Option (Right to Purchase) Award $0 +20,000 $0.000000 20,000 14 Oct 2023 Common Stock 20,000 $0.2900 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Janice McCourt is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On October 4, 2023, the reporting person was granted an option to purchase 20,000 shares of common stock of the issuer. The option vested in full following the satisfaction of certain performance criteria including the execution of a separation agreement and release by the reporting person and the expiration of a seven-day revocation period without the reporting person revoking the separation agreement and release.